HASSELT, Belgium--(BUSINESS WIRE)--MabCure, Inc. (OTCBB:MBCI) (“MabCure”), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, has been featured in a January 14, 2010 article published on GenomeWeb, the largest online news organization focused on advanced research tools in genomics, proteomics, and bioinformatics.
